Biotech Values

[DewDiligence]

(RVNC)—From a cursory scan of the PR you posted, I can assert that this “research” on the botulinum-toxin market is stale.

The $4.3B forecast for global botulinum-toxin sales in 2018 is almost certainly too low. Botox by itself is selling at an annualized rate of about $3B (#msg-124379793), and its 2Q16 sales grew 16% YoY in local currencies (14% YoY in dollars).

Mentor—one of the purported botulinum-toxin-companies mentioned in the PR you posted—was acquired by JNJ eight years ago (#msg-33879830), and JNJ dropped the program in 2014 (#msg-100466796).